Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Sequential Multiple Assignment Randomized Trial of Symptom Management After Chemotherapy.
Sikorskii A, Badger T, Segrin C, Crane TE, Chalasani P, Arslan W, Hadeed M, Morrill KE, Given C. Sikorskii A, et al. Among authors: chalasani p. J Pain Symptom Manage. 2023 Jun;65(6):541-552.e2. doi: 10.1016/j.jpainsymman.2023.02.005. Epub 2023 Feb 17. J Pain Symptom Manage. 2023. PMID: 36801353 Free PMC article. Clinical Trial.
Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer.
Shagisultanova E, Gradishar W, Brown-Glaberman U, Chalasani P, Brenner AJ, Stopeck A, Parris H, Gao D, McSpadden T, Mayordomo J, Diamond JR, Kabos P, Borges VF. Shagisultanova E, et al. Among authors: chalasani p. Clin Cancer Res. 2023 Dec 15;29(24):5021-5030. doi: 10.1158/1078-0432.CCR-23-0117. Clin Cancer Res. 2023. PMID: 37363965 Free PMC article.
Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study.
Meric-Bernstam F, Calvo E, Lee KS, Moreno V, Park YH, Rha SY, Chalasani P, Zhong W, Zhou L, Pirie-Shepherd S, Leung ACF, Curigliano G. Meric-Bernstam F, et al. Among authors: chalasani p. Mol Cancer Ther. 2023 Oct 2;22(10):1191-1203. doi: 10.1158/1535-7163.MCT-23-0101. Mol Cancer Ther. 2023. PMID: 37420274 Free PMC article. Clinical Trial.
Immune Responses to COVID-19 mRNA Vaccines in Patients with Solid Tumors on Active, Immunosuppressive Cancer Therapy.
Shroff RT, Chalasani P, Wei R, Pennington D, Quirk G, Schoenle MV, Peyton KL, Uhrlaub JL, Ripperger TJ, Jergović M, Dalgai S, Wolf A, Whitmer R, Hammad H, Carrier A, Scott AJ, Nikolich-Žugich J, Worobey M, Sprissler R, Dake M, LaFleur BJ, Bhattacharya D. Shroff RT, et al. Among authors: chalasani p. medRxiv [Preprint]. 2021 Aug 25:2021.05.13.21257129. doi: 10.1101/2021.05.13.21257129. medRxiv. 2021. PMID: 34013289 Free PMC article. Updated. Preprint.
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.
Shroff RT, Chalasani P, Wei R, Pennington D, Quirk G, Schoenle MV, Peyton KL, Uhrlaub JL, Ripperger TJ, Jergović M, Dalgai S, Wolf A, Whitmer R, Hammad H, Carrier A, Scott AJ, Nikolich-Žugich J, Worobey M, Sprissler R, Dake M, LaFleur BJ, Bhattacharya D. Shroff RT, et al. Among authors: chalasani p. Nat Med. 2021 Nov;27(11):2002-2011. doi: 10.1038/s41591-021-01542-z. Epub 2021 Sep 30. Nat Med. 2021. PMID: 34594036 Free PMC article. Clinical Trial.
Nuclear epidermal growth factor receptor as a therapeutic target.
Atwell B, Chalasani P, Schroeder J. Atwell B, et al. Among authors: chalasani p. Explor Target Antitumor Ther. 2023;4(4):616-629. doi: 10.37349/etat.2023.00156. Epub 2023 Aug 30. Explor Target Antitumor Ther. 2023. PMID: 37720348 Free PMC article. Review.
89 results